恒瑞医药(01276.HK) 公布,子公司北京盛迪收到国家药监局核准签发关于SHR-8203注射液的药物临床试验批准通知书,同意本品单药在晚期实体瘤中开展临床试验。至今,SHR-8203注射液累计研发投入约2,040万人民币。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2026-08-20 16:25。)AASTOCKS新闻
Source Link恒瑞医药(01276.HK) 公布,子公司北京盛迪收到国家药监局核准签发关于SHR-8203注射液的药物临床试验批准通知书,同意本品单药在晚期实体瘤中开展临床试验。至今,SHR-8203注射液累计研发投入约2,040万人民币。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2026-08-20 16:25。)AASTOCKS新闻
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.